The Role of Endogenous Heparinization As an Intraoperative Predictive Marker for Postoperative ICU Admission

NCT ID: NCT06799949

Last Updated: 2025-02-07

Basic Information

• Recruitment Status: ACTIVE_NOT_RECRUITING
• Total Enrollment: 50 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2025-01-14
• Study Completion Date: 2025-04-30

Brief Summary

This prospective observational study investigates the role of endogenous heparinization as a predictive indicator for postoperative ICU admission. The phenomenon of endogenous heparinization is well documented with growing literature, investigating its clinical significance. The mechanisms leading to the pathogenesis of endogenous heparinization are the following: 1) Liver insufficiency in clearing circulating glycosaminoglycans (GAGs) due to acute liver failure, 2) Neutrophil-induced damage to hepatocytes, which results in releasing sulfated heparan, 3) Direct release of GAGs due to degradation of the endothelial glycocalyx. Furthermore, the endothelial glycocalyx shedding in response to pathological insults such as sepsis, ischemia-reperfusion injury, hyperglycemia, or trauma leads to increased vascular permeability, impaired microcirculation and systemic inflammation. This degradation is associated with several critical conditions, including acute kidney injury, cardiovascular diseases, and multi-organ failure, making glycocalyx shedding a crucial biomarker and therapeutic target. The aim of the study is to evaluate the correlation between intraoperative heparinization through the INTEM/HEPTEM ratio, as an indirect marker of endothelial glycocalyx integrity, and consequently, a biomarker of the patients' physiological status.

Detailed Description

This prospective study will include all adult patients scheduled for an elective or urgent major abdominal surgery, who are going to be evaluated preoperatively in our center (Ippokrateio General Hospital of Thessaloniki) The study will be conducted in compliance with ethical standards (Declaration of Helsinki) and has already obtained the approval of the scientific council (Ethics Committee) of our hospital. For every patient informed consent will be obtained. The justification of the request for preoperative ICU bed reservation is going to be based on three criteria: patient's ASA classification, the Surgical Risk score and the attending anaesthetist's opinion and clinical judgment. Patients undergoing neurosurgical, cardiovascular and transplantation procedures will be excluded. All patients will follow the preoperative anticoagulation/antiplatelet discontinuation guidelines. Patients' demographic data, medical history and the necessary laboratory evaluation will be recorded. On the day of the operation the standard anesthetic protocol according to the type of the surgery will be followed and the ESAIC (European Society of Anaesthesia and Intesive Care) standard monitoring will be deployed. All patients are going to receive general anaesthesia. The use of locoregional anaesthesia (epidural, spinal, combined and nerve blocks) mechanical ventilation parameters, hemodynamic parameters, fluid management, ABG analysis results will be recorded in a thorough manner. After anaesthesia induction an arterial line will be placed for direct measurement of arterial pressure, blood gas monitoring of the patient, and simultaneous collection of samples for ROTEM (TEM Innovations GmbH, Munich, Germany) assays. For each patient, two samples will be collected for ROTEM analysis: one at the beginning of the surgery during the placement of the arterial line (Start ratio) and another at the end during the completion of the surgical wound closure(Final ratio). The arterial line system will be filled with normal saline (0.9% sodium chloride) without the addition of unfractionated heparin. To avoid sample contamination before sampling, a volume of blood equivalent to 5.5-6 times the dead space (calculated from the catheter tip to the three-way stopcock device) will be aspirated. Blood samples for testing will be stored in specialized evacuated coagulation test tubes (Jiangsu Rongye Technology Co., Ltd, Jiangsu, China) and gently mixed with 3.2%-0.109M sodium citrate, for a total volume of 1.8 ml. At the end of the surgery, the decision for the patient's postoperative ICU admission will be based on those criteria

• Mental status: Awake and cooperative.
• Oxygenation: PaO₂/FiO₂ ratio ≥ 150-200.
• Ventilation: PaCO₂ < 50 mmHg or baseline.
• RSBI<105.
• Respiratory effort: Spontaneous breathing, no excessive work of breathing.
• Cardiovascular:HR < 140/min; SBP 90-160 mmHg with minimal to no vasopressors.
• Neuromuscular function: TOF ratio ≥ 0.9.
• Attending anaesthetist's opinion and clinical judgement In case of the patients' successful extubation, the risk of re-intubation will be monitored for 24 hours.

Conditions

Heparinization

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Adult patients undergoing elective or urgent major abdominal surgeries

• Inclusion Criteria:

1. Adult patients (>18 years old) undergoing elective or urgent major abdominal surgeries.

2. ASA ≥ II and/or Surgical Risk score ≥ III

3. The attending anesthetist's opinion

• Exclusion Criteria:

1. Emergency surgeries where preoperative anticoagulant/antiplatelet discontinuation guidelines were not followed.

2. Patients with liver cirrhosis, trauma and sepsis.

3. Pregnant or women on reproductive age.

4. Children

5. Neurosurgical, cardiovascular and transplantation procedures

6. Patient's refusal to participate

ROTEM (TEM Innovations GmbH, Munich, Germany) assay

Intervention Type: DIAGNOSTIC_TEST

For each patient, two samples will be collected for ROTEM analysis: one at the beginning of the surgery, during the placement of the arterial line (Start ratio), and another one, at the end, during the completion of the surgical wound closure (Final ratio). The arterial line system will be filled with normal saline (0.9% sodium chloride) without the addition of unfractionated heparin. To avoid sample contamination before sampling, a volume of blood equivalent to 5.5-6 times the dead space (calculated from the catheter tip to the three-way stopcock device) will be aspirated. Blood samples for testing will be stored in specific empty coagulation test tubes (Jiangsu Rongye Technology Co., Ltd, Jiangsu, China) and gently mixed with 3.2%-0.109M sodium citrate, for a total volume of 1.8 ml.

Interventions

ROTEM (TEM Innovations GmbH, Munich, Germany) assay

For each patient, two samples will be collected for ROTEM analysis: one at the beginning of the surgery, during the placement of the arterial line (Start ratio), and another one, at the end, during the completion of the surgical wound closure (Final ratio). The arterial line system will be filled with normal saline (0.9% sodium chloride) without the addition of unfractionated heparin. To avoid sample contamination before sampling, a volume of blood equivalent to 5.5-6 times the dead space (calculated from the catheter tip to the three-way stopcock device) will be aspirated. Blood samples for testing will be stored in specific empty coagulation test tubes (Jiangsu Rongye Technology Co., Ltd, Jiangsu, China) and gently mixed with 3.2%-0.109M sodium citrate, for a total volume of 1.8 ml.

Intervention Type: DIAGNOSTIC_TEST

Eligibility Criteria

Inclusion Criteria

• Adult patients (>18 years old) undergoing elective or urgent major abdominal surgery.
• ASA ≥ II and/or Surgical Risk score ≥ III
• The attending anesthetist's opinion

Exclusion Criteria

• Emergency surgeries where preoperative anticoagulant/antiplatelet discontinuation guidelines were not followed.
• Patients with liver cirrhosis, trauma and sepsis.
• Pregnant or women on reproductive age.
• Children
• Neurosurgical, cardiovascular and transplantation procedures
• Patient's refusal to participate

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kotoulas Serafeim-Chrysovalantis

OTHER

Sponsor Role: lead

Responsible Party

Kotoulas Serafeim-Chrysovalantis

Principal Investigator

Responsibility Role: SPONSOR_INVESTIGATOR

Locations

Ippokrateio General Hospital of Thessaloniki

Thessaloniki, Thessaloniki, Greece

Countries

Greece

Other Identifiers

Ε.Σ.: 842 / 14-01-2025

Identifier Type: -

Identifier Source: org_study_id